CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
19 hedge funds and large institutions have $1.12M invested in CASI Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 4 closing their positions.
3.6% less ownership
Funds ownership: 6.98% → 3.38% (-3.6%)
10% less funds holding
Funds holding: 21 → 19 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
94% less capital inflows, than outflows
Capital inflows: $82.9K | Capital outflows: $1.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$75.7K |
| 2 |
Renaissance Technologies
New York
|
+$5.38K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.77K |
| 4 |
FA
Fiduciary Alliance
Greenville,
South Carolina
|
+$81 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$474K |
| 2 |
BlackRock
New York
|
-$245K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$204K |
| 4 |
WSC
Wellington Shields & Co
New York
|
-$143K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$88.2K |
CASI Hedge Fund Activity: Q2 2023 in Review
19 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2023, worth a combined $1.12M — down 48% from $2.15M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CASI and 2 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, opening a new position worth an estimated $75.7K. The largest seller was Vanguard Group, cutting an estimated $474K.
- 19 institutional investors held CASI Pharmaceuticals (CASI) as of Q2 2023, down from 21 in Q1 2023.
- Funds reported $1.12M of CASI Pharmaceuticals stock for Q2 2023, down 48% quarter-over-quarter.
- 2 funds opened new CASI Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of -2 holders.
- The largest CASI Pharmaceuticals buyer in Q2 2023 was Jane Street, an estimated $75.7K added.
- The largest CASI Pharmaceuticals seller in Q2 2023 was Vanguard Group, an estimated $474K sold.
Based on aggregated 13F filings for Q2 2023.